Sutro, Celgene collaborate on R&D of antibody drugs

12/19/2012 | Genetic Engineering & Biotechnology News

Sutro Biopharma agreed to design and develop new antibody-drug conjugates and bispecific antibodies against two undisclosed targets for Celgene using its cell-free protein synthesis technology. The deal also covers the production of a proprietary Celgene antibody. In return, Celgene will give Sutro an upfront payment and as much as $500 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA